Overview

Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)

Status:
Not yet recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Treatments:
Cisplatin
Gemcitabine